Haddadin Yezan Munther's Form 4 filing
Outlook Therapeutics, Inc. (OTLK) · filed Oct 11, 2022
- Accession no.
- 0001209191-22-053354
- Filed
- Oct 11, 2022
- Trade date
- Oct 6-7, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $42.9K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Haddadin Yezan MuntherCIK 0001718004 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2022 | Common Stock | PPurchaseAcquired | +29,743 | $1.29 | +$38,368.47 | 59,743 | Direct | |
| Oct 7, 2022 | Common Stock | PPurchaseAcquired | +3,600 | $1.27 | +$4,572 | 63,343 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.